Generic
Diphtheria Tetanus Pertussis Poliomyelitis Vaccine
At a glance
Diphtheria, Tetanus, Pertussis, Poliomyelitis Vaccine is a combination vaccine used for primary vaccination in infants from 2 months and booster vaccination.
Description
This vaccine is used for the active immunisation of diphtheria, tetanus, pertussis, and poliomyelitis.
Indications
- Primary vaccination in infants from 2 months of age
- Booster vaccination during the second year of life
- Booster vaccination between 5 and 13 years of age
Therapeutic class
Vaccines, Anti-sera & Immunoglobulin
Pharmacological class
Combination Vaccine (DTP + IPV)
Pharmacology
This vaccine is used for the active immunisation of diphtheria, tetanus, pertussis, and poliomyelitis.
Mechanism of action
The vaccine stimulates the production of specific antibodies against diphtheria, tetanus, pertussis, and poliomyelitis by introducing antigens and triggering an immune response.
Dosage
Child (Primary vaccination): 3 injections (0.5 mL) at 2, 3, 4 months (1-month intervals).
Booster vaccination: 1 injection one year after primary vaccination (usually 16-18 months); 1 injection between 5-13 years.
Administration
Administer as a deep intramuscular injection (antero-lateral thigh in infants, deltoid area in children).
Missed dose
The vaccine is administered by healthcare professionals. You cannot miss a dose yourself.
Side effects
Common: Local injection-site reactions (pain, redness, swelling), abnormal crying, loss of appetite, irritability (usually within 48 hours, may continue for 48-72 hours).
Booster vaccination: Frequency of injection-site reactions tends to increase.
Children aged 2 years or more: Myalgia, malaise, headache.
Precautions & warnings
Immunogenicity may be reduced by immunosuppressive treatment or immunodeficiency; wait until end of treatment. Vaccination recommended in HIV infection. Caution in Guillain-Barre syndrome or brachial neuritis history. Caution in thrombocytopenia or bleeding disorders.
Contraindications
Hypersensitivity (active substances, excipients, glutaraldehyde, neomycin, streptomycin, polymyxin B, pertussis vaccine); life-threatening reaction after previous vaccination; febrile or acute disease; evolving encephalopathy; encephalopathy within 7 days of previous pertussis-containing vaccine.
Drug interactions
M-M-RVAXPRO or HBVAXPRO: Can be administered simultaneously but at separate sites.
Haemophilus influenzae type b conjugate vaccine (Act-HIB): Can be associated or combined.
Food interactions
Can be used with or without food.
Use in pregnancy
No adequate data available to assess vaccine-associated risks in pregnancy.
Pregnancy Category: N/A — always consult a doctor before taking during pregnancy.
Use in lactation
No adequate data available to assess vaccine-associated risks in lactation.
Pediatric use
Indicated for infants from 2 months of age.
Geriatric use
Not indicated for elderly patients.
Renal / hepatic impairment
No special precautions are necessary for patients with kidney or liver problems.
Overdose effects
No adequate information on overdose is available.
Storage conditions
Store at +2°C to +8°C. Do not freeze. Protect from light.
Chemical structure
Diphtheria Tetanus Pertussis Poliomyelitis Vaccine